Enlaces de acceso:
CONTENIDO
Destacados
Virología e Immunología Celular
Publicaciones
-
Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue...
doi:10.1186/1479-5876-11-68
BackgroundChronic Fatigue Syndrome (CFS) is a debilitating neuro-immune disorder of unknown etiology diagnosed by an array...
-
Dynamic Imaging of Cell-Free and Cell-Associated Viral Capture in Mature Dendritic Cells
Traffic. 2011 Dec;12(12):1702-13. doi: 10.1111/j.1600-0854.2011.01281.x. Epub 2011 Oct 10
Dendritic cells (DCs) capture human immunodeficiency virus (HIV) through a non-fusogenic mechanism that enables viral...
-
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a...
Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.
Background: Residual viraemia is a major obstacle to HIV-1 eradication in subjects receiving HAART. The intensification...
-
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity
Vaccine. 2011 Jul 18;29(32):5250-9. doi: 10.1016/j.vaccine.2011.05.016. Epub 2011 May 24
BACKGROUND: Cell-to-cell HIV spread through virological synapses proceeds in two steps, first HIV particles are rapidly...
Seminarios y Congresos
AIDS Vaccine 2013 - BARCELONA
07.10.13bb AIDS Vaccine is the largest and most diverse international meeting of researchers, advocates, clinicians, private sector partners and...
- 19.03.13 - 19.03.13
[IrsiCaixa Seminar] Will it be possible to live without cART? Natural and induced control of HIV-infection
IrsiCaixa Seminar: Will it be possible to live without cART? Natural and induced control of HIV-infection
Lecturer: Asier Sáez-Cirión.
Más información - 11.03.13 - 11.03.13
POST-CROI 2013: 20th Conference on Retroviruses and Opportunistic Infections Update
When: March 11th 2013. 2.30pm
Where: Auditori de La Pedrera. Passeig de Gràcia, 92. Barcelona
Proyectos
Effect of PEG-Interferon alfa 2a on T-cell activation markers in HIV/HCV chronically infected individuals
Entidad finanzadora: ORVACS
Entidad(es) participant(es): Fundació IrsiCaixa
